Home Inherited Disease and Carrier Screening Pompe Disease Genetic Test: GAA Gene Mutations, Carrier Risk, and Results

Pompe Disease Genetic Test: GAA Gene Mutations, Carrier Risk, and Results

By
Vita Library
-
4
Understand GAA genetic testing for Pompe disease, including enzyme confirmation, carrier risk, pseudodeficiency, newborn screening, and positive or uncertain results.

A Pompe disease genetic test analyzes the GAA gene for inherited variants that reduce acid alpha-glucosidase activity. Pompe disease is an autosomal recessive lysosomal storage disorder in which glycogen builds up, especially in skeletal, respiratory, and cardiac muscle. Testing can confirm a diagnosis after low enzyme activity or a positive newborn screen, identify carriers, clarify relatives’ risks, and provide the familial variants needed for reproductive testing.

DNA results should not be interpreted alone. Diagnosis usually depends on the combination of GAA enzyme activity, two disease-causing GAA variants, symptoms, and supporting tests. Some GAA variants cause pseudodeficiency, meaning enzyme activity appears low in a laboratory assay even though the person does not have Pompe disease. Other variants retain enough activity to produce later-onset disease rather than severe infantile disease. The most useful report explains both variants, whether they are on opposite gene copies, the expected effect on enzyme function, and any limitations that could leave a second variant undetected.

  • Pompe disease usually requires pathogenic variants in both copies of GAA.
  • One pathogenic GAA variant usually indicates carrier status, not disease.
  • Low dried-blood-spot enzyme activity is a screening clue and needs confirmatory testing.
  • Pseudodeficiency variants can lower measured enzyme activity without causing Pompe disease.
  • Infantile-onset disease requires urgent evaluation because early treatment can change outcomes.
  • A negative sequencing result may need deletion/duplication analysis or broader review if enzyme deficiency is convincing.

Table of Contents

What Pompe testing measures

The GAA gene provides instructions for acid alpha-glucosidase, a lysosomal enzyme that breaks glycogen into glucose. When both GAA copies have disease-causing variants, enzyme activity can fall enough for glycogen to accumulate inside lysosomes. Enlarged and disrupted lysosomes interfere with muscle-cell function and contribute to progressive weakness.

Pompe disease spans a continuum rather than two perfectly separate disorders. Classic infantile-onset Pompe disease usually presents in the first months of life with severe low muscle tone, weakness, feeding difficulty, respiratory problems, and hypertrophic cardiomyopathy. Residual GAA activity is often extremely low. Late-onset Pompe disease may begin in childhood, adolescence, or adulthood and commonly causes limb-girdle and trunk weakness, diaphragm weakness, sleep-related hypoventilation, reduced respiratory function, fatigue, and difficulty climbing stairs or rising from a chair. Major cardiomyopathy is much less typical in later-onset disease.

A molecular test looks for sequence changes and, when included, deletions or duplications in GAA. These can include missense variants, nonsense variants, splice variants, small insertions or deletions, and larger missing gene segments. The laboratory classifies findings as pathogenic, likely pathogenic, uncertain, likely benign, or benign.

The genetic test answers a different question from the enzyme assay. DNA testing asks whether the person has inherited variants capable of causing deficient GAA production or function. Enzyme testing measures the biochemical result under specific laboratory conditions. Both are important because low activity can result from true disease, carrier status, sample problems, or pseudodeficiency, while DNA testing can occasionally miss a second pathogenic change.

Pompe disease is one of several inherited conditions that can cause muscle weakness or elevated creatine kinase. A broader genetic panel may be considered when the clinical picture is not specific, but a rapid GAA enzyme assay is often an efficient first clue when Pompe disease is suspected.

When GAA testing is used

Testing may begin because of symptoms, an abnormal newborn screen, a known family diagnosis, or reproductive planning. The urgency and best sequence of tests differ in each setting.

Diagnostic testing for symptoms

Clinicians may consider Pompe disease when an infant has hypotonia, enlarged heart, feeding problems, respiratory distress, poor growth, or markedly delayed motor development. In older children and adults, clues include progressive proximal weakness, waddling gait, difficulty with stairs, unexplained diaphragm weakness, morning headaches from nighttime hypoventilation, or respiratory impairment that seems greater than limb weakness.

These findings overlap with muscular dystrophies, inflammatory muscle disease, congenital myopathies, motor neuron disorders, mitochondrial disease, and other metabolic myopathies. Creatine kinase may be elevated but can be normal or only mildly increased, so it cannot exclude Pompe disease.

Follow-up of newborn screening

Many newborn screening programs measure GAA activity in a dried blood spot. A screen-positive infant needs prompt confirmatory evaluation. The screen does not distinguish with certainty among classic infantile disease, later-onset disease, carrier status, pseudodeficiency, and a false-positive result.

Testing relatives

Once two familial pathogenic variants are known, siblings and other relatives can have targeted testing. This can identify affected relatives before symptoms, carriers for reproductive counseling, and relatives who did not inherit either familial variant.

Carrier and reproductive screening

Carrier screening may include GAA on an expanded recessive panel or may be ordered because of family history. A carrier generally has one pathogenic GAA variant and one functioning copy. Carriers are not expected to develop Pompe disease, although their enzyme activity can overlap with the low end of the normal range and should not be used alone to define carrier status.

A person with one known variant and a reproductive partner who is also a carrier has a 25% chance in each pregnancy of a child with Pompe disease, a 50% chance of a carrier child, and a 25% chance of a child who inherited neither familial variant. These probabilities apply independently to every pregnancy.

Clarifying an unresolved biochemical result

Genetic testing is essential when GAA activity is low but the phenotype is unclear. Finding two pathogenic variants that fit the enzyme result supports diagnosis. Finding only pseudodeficiency variants explains a low assay without disease. Finding one pathogenic variant may indicate carrier status, a missed second variant, or an unrelated cause of symptoms.

How enzyme and DNA testing work together

A well-designed evaluation treats enzyme activity and genotype as complementary evidence.

Dried blood spot screening

A dried blood spot is convenient and sensitive, which makes it useful for newborn screening and initial testing. It is not usually the final diagnostic assay. Temperature, transport, white-cell count, assay platform, and pseudodeficiency can affect the measurement. An abnormal result should trigger confirmatory testing rather than immediate labeling of the child or adult as affected.

Confirmatory enzyme testing

Laboratories may measure GAA activity in leukocytes, lymphocytes, cultured skin fibroblasts, or other validated specimens. Leukocyte or lymphocyte testing can provide a faster confirmatory result than a cell culture. Fibroblasts may be useful when blood results are unclear or sample history complicates interpretation.

Very low activity is typical of classic infantile disease, while greater residual activity is more often associated with later-onset disease. The ranges overlap, however, and a laboratory value should not be used as an exact age-of-onset prediction.

Molecular testing

GAA sequencing detects most small pathogenic variants. Deletion/duplication analysis is needed to detect certain exon-level or larger changes. Some assays combine both methods; others perform deletion/duplication testing only after sequencing finds zero or one variant. The report should make this clear.

When two variants are found, determining whether they are in trans is important. In trans means one variant is on the maternally inherited GAA copy and the other is on the paternally inherited copy. That arrangement is consistent with autosomal recessive disease. Two variants in cis, on the same chromosome copy, leave the other GAA copy unaffected and usually do not establish Pompe disease. Testing parents can often determine phase.

Supporting biomarkers and clinical studies

Urinary glucose tetrasaccharide, often called Glc4, may be elevated because of glycogen breakdown and can support diagnosis or monitoring. Creatine kinase, liver enzymes, cardiac biomarkers, electrocardiogram, echocardiogram, pulmonary function, sleep testing, muscle imaging, and physical assessment may also be used according to age and presentation.

The result is strongest when all parts agree: compatible symptoms or a newborn-screening indication, clearly deficient enzyme activity, and two pathogenic GAA variants in trans. Discordant results require review rather than forcing one test to overrule the others.

How to interpret genetic results

The number and classification of GAA variants shape the report, but the enzyme result and phenotype determine what the finding means for the person.

Two pathogenic or likely pathogenic variants

Two disease-causing variants in trans usually confirm Pompe disease when GAA activity is deficient. “Likely pathogenic” is a formal evidence-based category and is generally managed like pathogenic in diagnostic interpretation. The report may discuss published cases, functional evidence, predicted protein effect, population frequency, and known association with infantile- or later-onset disease.

A confirmed genotype does not guarantee one precise clinical course. Some variant combinations are strongly associated with classic infantile disease, while others usually retain partial function and produce later onset. Even relatives with the same variants may differ in symptom timing and progression.

One pathogenic or likely pathogenic variant

One pathogenic variant most often means the person is a carrier. In someone with normal enzyme activity and no compatible symptoms, carrier status is the likely conclusion.

In a person with clearly deficient GAA activity or convincing Pompe features, one finding is incomplete. The second variant may be a deletion, duplication, deep intronic change, complex rearrangement, or variant not recognized by the assay. The clinician may request deletion/duplication analysis, reanalysis, RNA studies, genome sequencing, or testing in a laboratory with broader coverage.

No pathogenic variants

A negative result lowers the likelihood of Pompe disease but does not have the same meaning in every context. If confirmatory enzyme activity is normal, Pompe disease is unlikely. If enzyme activity is repeatedly and clearly deficient, the laboratory method and alternative explanations need review. The diagnosis should not be dismissed solely because a limited sequencing assay was negative.

Variant of uncertain significance

A VUS is not proven to cause disease and should not be treated as a positive result by itself. Two VUS findings do not automatically establish Pompe disease. Evidence may come from enzyme studies, family segregation, RNA analysis, functional assays, population databases, and future case reports. Clinical decisions should rest on the full diagnostic evidence while the variant remains uncertain. A VUS explanation can help families understand why uncertainty is a real result category rather than an error.

Pseudodeficiency variants

Pseudodeficiency variants reduce measured GAA activity on certain artificial laboratory substrates but do not cause the glycogen accumulation and progressive muscle disease of Pompe disease. They are particularly important in newborn screening because they can create a low-activity result in a healthy infant. Some pseudodeficiency variants are more common in people with East Asian ancestry, but ancestry should never substitute for molecular interpretation.

A report may find pseudodeficiency variants alone, together with a pathogenic variant, or as part of a complex allele. The laboratory should explain the configuration. Pseudodeficiency is not a mild form of Pompe disease and generally does not require enzyme replacement therapy.

Benign findings

Benign and likely benign variants do not explain Pompe disease. They may be omitted from the final report or listed separately. A clear understanding of these formal categories is available in a genetic variant result guide.

Carrier status and family risk

Pompe disease is inherited in an autosomal recessive pattern. A person with Pompe disease usually inherited one disease-causing GAA variant from each parent. The parents are typically unaffected carriers, although exceptions include a new variant, uniparental inheritance, or parental mosaicism.

For two carrier parents, each pregnancy has:

  • A 25% chance of a child with two familial variants and Pompe disease
  • A 50% chance of a child with one variant who is a carrier
  • A 25% chance of a child with neither familial variant

An affected person generally passes one pathogenic variant to every biological child. The child develops Pompe disease only if the other parent also contributes a disease-causing GAA variant. Therefore, testing the reproductive partner can clarify risk.

Carrier screening is not perfectly sensitive. A partner with a negative result has a reduced, not always zero, chance of being a carrier. Residual risk depends on the assay’s coverage, whether deletion/duplication analysis was included, the laboratory’s classification rules, and the partner’s population background. A negative enzyme assay is not a reliable substitute for molecular carrier testing because carrier and non-carrier activity ranges can overlap.

When the familial variants are known, reproductive options may include natural conception, prenatal diagnosis by chorionic villus sampling or amniocentesis, or in vitro fertilization with preimplantation genetic testing for a monogenic disorder. Donor gametes, adoption, and choosing not to test are also valid options. Testing should target established pathogenic or likely pathogenic variants, not an unresolved VUS.

Siblings of a person with Pompe disease may be affected, carriers, or unaffected. Adult siblings should be offered counseling and testing even if they feel well because later-onset disease can remain unrecognized for years. Children who may have inherited two familial variants need age-appropriate clinical evaluation; this is not merely predictive testing for an untreatable adult condition.

Extended relatives may also be carriers. Once the family variants are documented, a concise family letter can help relatives seek targeted testing. The laboratory report should be shared in full rather than relying on a verbal description such as “positive for Pompe.” General principles of autosomal recessive testing apply to these family decisions.

Newborn screening and urgent infant evaluation

A positive Pompe newborn screen is time-sensitive because classic infantile disease can progress rapidly and treatment should not wait for advanced muscle or heart damage. At the same time, the screen is not a diagnosis, and families need careful communication to avoid assuming the baby is definitely affected.

Confirmatory evaluation commonly includes repeat GAA enzyme activity in a validated diagnostic specimen, GAA sequencing with deletion/duplication analysis, physical and neurologic examination, creatine kinase and other laboratory markers, electrocardiogram, echocardiogram, and urinary Glc4. The exact protocol varies by screening program and metabolic center.

Results may identify:

  1. Classic infantile-onset Pompe disease: very low enzyme activity, two pathogenic variants, and often cardiomyopathy or other early signs.
  2. Presumed later-onset Pompe disease: deficient enzyme activity and two pathogenic variants but no infantile cardiomyopathy or major symptoms at present.
  3. Carrier status: one pathogenic variant without diagnostic biochemical evidence.
  4. Pseudodeficiency: variants that explain low screening activity without disease.
  5. Unresolved or false-positive result: findings that require repeat testing or follow-up.

Infants with confirmed or strongly suspected classic disease need urgent referral to a specialized metabolic and neuromuscular team. The team also determines cross-reactive immunologic material, or CRIM, status. CRIM-negative infants produce no detectable native GAA protein and are at high risk of developing strong antibodies against infused enzyme replacement therapy. Genotype can sometimes predict CRIM status; protein testing may be used when it cannot. Immune-tolerance treatment may be considered around the start of enzyme therapy.

A baby categorized as later-onset does not necessarily need immediate treatment while asymptomatic, but does need a structured surveillance plan. Families should know which clinic will monitor motor development, strength, respiratory function, laboratory markers, and emerging symptoms. The label “late onset” does not identify the exact decade in which symptoms will appear.

Newborn-screening follow-up should also include parental testing when useful, explanation of recurrence risk, and documentation of both variants. A newborn screening guide can help distinguish screening from diagnosis, but local metabolic specialists should direct the infant’s timeline.

Genotype, treatment, and monitoring

Genotype helps confirm disease, estimate residual enzyme production, identify CRIM risk in infants, and place a person within a broad phenotype range. It does not replace direct assessment of muscle, breathing, swallowing, cardiac function, mobility, fatigue, and daily participation.

Enzyme replacement therapy supplies recombinant GAA through intravenous infusions. Several products and dosing approaches are used according to age, country, clinical status, and regulatory approval. Treatment can improve survival and cardiac outcomes in infantile disease and can stabilize or improve motor and respiratory measures in many people with later-onset disease. Response varies, and established muscle damage may not fully reverse.

Monitoring is multidisciplinary. Depending on presentation, it may include:

  • Motor testing, gait, strength, and timed functional measures
  • Upright and supine forced vital capacity
  • Sleep assessment and noninvasive ventilation review
  • Swallowing, nutrition, and growth evaluation
  • Cardiac imaging and rhythm studies, especially in infants
  • Hearing, speech, and developmental assessment in young children
  • Laboratory biomarkers and antibody monitoring during therapy
  • Physical therapy, respiratory therapy, and assistive-device planning

A person with a later-onset-associated genotype who feels well still needs periodic assessment because diaphragm weakness can precede obvious limb disability. Symptoms such as breathlessness when lying flat, morning headache, restless sleep, daytime sleepiness, repeated chest infections, unexplained falls, or declining ability to climb stairs should prompt review.

Treatment decisions should not be based on a VUS or a single carrier variant. Conversely, care should not be delayed in a critically ill infant while every molecular detail is being resolved if enzyme deficiency and the clinical picture strongly support classic Pompe disease. The metabolic team balances diagnostic certainty with the cost of irreversible delay.

Pregnancy requires individualized review of respiratory reserve, muscle function, nutrition, infusion plans, and medication safety. People with significant diaphragm weakness may need closer pulmonary monitoring. Genetic counseling should address both the affected parent’s health and the child’s inheritance risk.

Limitations and next steps

A high-quality result should answer four questions: What variants were found? Are they disease-causing? Are they on opposite GAA copies? Do the enzyme and clinical findings agree?

If the report is incomplete, ask whether sequencing covered all coding exons and splice boundaries, whether deletion/duplication analysis was performed, and whether known complex alleles were considered. Some GAA variants occur together on the same chromosome, so phase can change the interpretation. Parental testing is often the simplest way to establish it.

Low-level mosaicism is uncommon but possible. A blood result may not detect a variant present in only a small proportion of cells. A prior allogeneic bone marrow or stem-cell transplant can also make blood DNA represent the donor rather than the patient; the laboratory may need a non-blood specimen such as cultured skin fibroblasts.

Do not use home ancestry data or a consumer genotyping array to confirm Pompe disease or carrier status. These products test selected sites and can miss most rare GAA variants. A clinically important consumer finding needs confirmation in an accredited diagnostic laboratory.

When testing finds one variant but enzyme activity and symptoms strongly suggest Pompe disease, next steps may include:

  • Confirming the enzyme result in another specimen
  • Reviewing the raw molecular data and coverage
  • Adding deletion/duplication analysis
  • Testing RNA for a suspected splice defect
  • Using genome or long-read sequencing for a complex variant
  • Reassessing whether pseudodeficiency or another neuromuscular disorder better explains the findings

When two VUS findings are reported, family testing may help, but it should be coordinated by the laboratory or genetics team. A variant found in healthy older relatives can argue against a severe fully penetrant effect, while co-segregation with enzyme deficiency and disease can add support. These data rarely convert uncertainty into certainty during a single appointment.

Keep the original GAA report, enzyme values with laboratory reference ranges, newborn-screening record if relevant, and treatment records. Variant classifications and genotype-phenotype knowledge change over time. Reanalysis is particularly valuable when the diagnosis remains unresolved, a variant is uncertain, or new symptoms do not match the original conclusion.

Urgent medical assessment is appropriate for an infant with poor feeding, increasing sleepiness, breathing difficulty, bluish color, severe weakness, or known cardiomyopathy; for any person with rapidly worsening breathing or inability to clear secretions; and for new choking or aspiration concerns. Genetic test interpretation is important, but immediate respiratory and cardiac safety comes first.

References

Disclaimer

This article is for general education and does not diagnose Pompe disease or determine treatment. Low GAA activity, genetic findings, cardiac status, respiratory function, and symptoms require interpretation by a metabolic or neuromuscular specialist and a qualified genetics professional. A positive newborn screen or an infant with weakness, feeding difficulty, breathing problems, or cardiomyopathy requires prompt clinical evaluation.

RELATED ARTICLESMORE FROM AUTHOR